Amgen, a CataloniaBio & HealthTech member, and Adaptative Biotechnologies announced a collaboration aimed at helping address the Covid-19 pandemic. The two companies will pool their expertise to discover and develop fully human neutralising antibodies targeting SARS-CoV-2 to potentially prevent or treat Covid-19. 

"Our strong history of collaboration with Adaptive gives us the ability to immediately mobilise our combined resources to help address the urgency in controlling this global pandemic," says  Fina Lladós, general manager of Amgen Iberia, which has a subsidiary in Barcelona.

Adaptive will extend its high throughput platform to screen the massive genetic diversity of the B cell receptors from patients who have recovered from Covid-19. Amgen will then leverage its world-class antibody engineering and drug-development capabilities to select, develop and manufacture antibodies designed to bind to and neutralise SARS-CoV-2.

More information

Photo: Fina Lladós, general manager of Amgen Iberia - © L'Econòmic, Josep Losada